Pracipio ANTICIPATE . ADVISE . ADVANCE
Anticipate . Advise . Advance

Evidence-driven strategy for pharma, biotech and consumer health.

When a decision is too expensive to get wrong, you want the best available expertise on your side of the table. Pracipio brings senior-led analysis, primary evidence and decision models that de-risk development, launch and investment choices.

Talk to us See recent work
Currently in focus AI in clinical development & regulatory affairs — protocols and dossiers should no longer be written by hand.
What we do

Four ways we put evidence behind your decisions

Every engagement is senior-led and built on primary evidence — expert input, real-world data and transparent models your board, investors and payers can interrogate.

Strategy & Business Development

Portfolio, launch and go-to-market strategy; partnering and licensing support; transaction due diligence; fundraising narratives that stand up to investor scrutiny.

Expert Insight & Primary Research

Structured expert interviews, quantitative surveys and KOL programmes — designed, fielded and analysed to answer the specific question your strategy hangs on.

Pragmatic Trials & Patient-Reported Outcomes

Pragmatic trial and PRO endpoint design, statistical analysis plans, and the internal and external communication of patient-outcome results.

HEOR, Market Access & Value

Value dossiers, pricing and reimbursement strategy, and real-world evidence that carries negotiations with payers and HTA bodies.

Recent work

Engagements where the stakes were high

A selection of recent project types. Details are anonymised and blended to protect client confidentiality — ask us about the ones that sound like your problem.

Portfolio strategy

ADC portfolio triage under a burning cash runway

A clinical-stage biotech with twenty assets was burning cash faster than any funding round could cover. We prioritised the portfolio against tractable indications, shaped a CDMO partnering strategy, and rebuilt the investor narrative around the assets worth betting on.

→ A fundable story, and a portfolio the team could actually afford to develop.

Radiopharmaceuticals

Just-in-time logistics for a decaying product

Radioligand therapies expire by physics, not by shelf-life policy. For early entrants in the class we designed demand-and-capacity prediction models and supply-chain planning tools where none existed — enabling just-in-time delivery to treatment sites.

→ Planning tools the category had never had, still in weekly use.

Cell & gene therapy

Forecasting demand for one-shot therapies

For a marketed CAR-T therapy we built demand forecasts, manufacturing slot scheduling and patient-flow models that fed weekly commercial and operations decisions across markets — for years, not as a one-off study.

→ A forecasting capability embedded in the client's routine, season after season.

Patient-reported outcomes

PRO strategy from protocol to payer narrative

Across several recent programmes we designed the PRO components of pivotal trial protocols, wrote the statistical analysis plans, and planned how patient-outcome results would be communicated — internally, to regulators and to the market.

→ Patient-outcome evidence designed to be used, not archived.

Market access

Value dossiers that survive the negotiation room

For products facing sceptical payers we synthesised clinical, economic and real-world evidence into value dossiers built for pricing and reimbursement negotiations across European markets — and supported the negotiations themselves.

→ Reimbursement secured on evidence, not on discounting alone.

Data & AI readiness

Making regulated data AI-ready — compliantly

A company's decades of studies, documents and datasets sat scattered across silos no AI could safely touch. We designed the consolidation into a 21 CFR Part 11-compliant central repository with governed AI access — value from archives without regulatory exposure.

→ One compliant repository; every past study a queryable asset.

All examples are composites of real engagements, anonymised and blended. References available in confidence where clients permit.

Perspectives

What we are telling clients right now

Q3 2026

The patent cliff is a strategy stress test

With well over $200 billion of branded revenue exposed to loss of exclusivity by 2030, "wait and see" is a decision — usually the wrong one. The winners are already re-basing portfolios, pruning tail assets and buying growth while valuations are still reasonable. The question is not whether the cliff hits your P&L, but whether your answer is built before or after your competitors build theirs.

Q3 2026

Dossiers were never meant to be handwritten

Clinical protocols, value dossiers and regulatory submissions remain overwhelmingly artisanal — expensive experts hand-crafting documents that are 80% structure and precedent. AI now drafts that 80% credibly, when the underlying data is consolidated and compliant. The bottleneck has moved from writing to data readiness and expert review. Firms that reorganise around that reality will file faster and cheaper than those that don't.

Q3 2026

The funding thaw rewards prepared stories

After several brutal years, biotech funding is flowing again — selectively. Investors have not lowered the bar; they have raised it and started writing cheques to those who clear it. The difference between a term sheet and a pass is increasingly the quality of the evidence behind the story: portfolio logic, honest burn maths and independent validation of the science and the market. Spring is here for the prepared.

Where to meet us

On the road, where the industry gathers

Conferences we expect to attend over the coming months. Planning to be at one of them? Write ahead and we'll set aside time to meet.

Email us to arrange a meeting →

About Pracipio

Senior-led. Evidence-obsessed. Since 1999.

Pracipio is a London-based strategy consultancy for pharmaceuticals, biotech and consumer health. Our consultants have advised the industry since 1999 — inside pharma, in leading consultancies, and since 2012 under the Pracipio name.

Every engagement is led by principal-level consultants and supported by a network of specialist associates and partner organisations across Europe, North America, the Middle East and Asia. We stay deliberately lean: you pay for expertise and evidence, not for pyramids of juniors.

We work where decisions are hardest — new modalities without precedents, evidence that must convince payers and regulators, portfolios under financial pressure — and we regularly attend and present at the industry's leading gatherings, from BIO and CPHI to ESMO, EANM and BioFIT.

We conduct our work in line with the industry's quality and ethics frameworks — including ISO 20252 on market research quality, the Market Research Society and EphMRA codes of conduct, GDPR and UK GDPR, and HIPAA where U.S. health information is involved — brought together in the Pracipio Code of Conduct. A copy is available on request.

25+ yearsadvising pharma, biotech and consumer health
200+ engagementsdelivered under the Pracipio name since 2012
Principal-ledevery project, end to end — no hand-offs to juniors
Contact

Tell us what you're facing

A short conversation is usually enough to tell whether we can help — and our policy is to come back with a proposed approach within 24 hours.

Email

felg@pracipio.com

Telephone

+44 7960 530 725

Office

4 Pentlow Street
London SW15 1LX
United Kingdom

Fredrik Elg, founder of Pracipio
Fredrik Elg Founder & Managing Director

Reach out to our founder to speak about your challenges — and how we can help you anticipate better, advise you with the best available evidence, and advance faster.

Start a conversation